Insider · CIK 0001750132
Anthony S Gibney
Files at AURA (Aura Biosciences, Inc.). First filing May 20, 2025, latest Jun 16, 2026.
In brief
Anthony S Gibney files SEC Form 4 as officer at AURA (Aura Biosciences, Inc.). Since May 20, 2025, Anthony S Gibney has reported 1 open-market buy worth $245k and 2 open-market sells worth $90k, the latest filed on Jun 16, 2026.
A track record needs three past buys with six months of prices behind them; Anthony S Gibney has 0, so none is measured yet.
The newest scored trade: sold $82k of AURA on Jun 16, 2026, filed Jun 16, 2026, scored 24 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $82k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AURA: Aura Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | AURAsell Aura Biosciences, Inc. | $82k 12,824 shares | -5% | +26% from low-29% from high | |
| 54Moderate | Aura Biosciences, Inc. | $245k 50,000 shares | +592% | +21% from low-49% from high | |
| 15Weak | AURAsell Aura Biosciences, Inc. | $7,823 1,519 shares | -3% | +21% from low-49% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 16, 2026 | AURA Aura Biosciences, Inc. | 12,824 0.01% of outstanding | $82k | Jun 16, 2026 | none |
| May 16, 2025 | AURA Aura Biosciences, Inc. | 1,519 0.00% of outstanding | $7,823 | May 16, 2025 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -12,824 | $6.42 | $82k | 265,354 | Jun 16, 2026 |
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +71,245 | $0.00 | $0 | 278,178 | Mar 3, 2026 |
| Mar 2, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +128,755 | $0.00 | $0 | 128,755 | Mar 3, 2026 |
| Jun 2, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 206,933 | Jun 4, 2025 |
| Jun 2, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jun 4, 2025 |
| May 16, 2025 | AURA Aura Biosciences, Inc. | POpen-market purchase Common Stock | +50,000 | $4.90 | $245k | 58,452 | May 20, 2025 |
| May 16, 2025 | AURA Aura Biosciences, Inc. | SOpen-market sale Common Stock | -1,519 | $5.15 | $7,823 | 56,933 | May 20, 2025 |
| May 16, 2025 | AURA Aura Biosciences, Inc. | POpen-market purchase Common Stock Warrants (right to buy)derivative | +12,500 | - | - | 12,500 | May 20, 2025 |
Questions about Anthony S Gibney
Answered from the filings on this page, as of the latest one.
Is Anthony S Gibney buying or selling?
In the last 12 months Anthony S Gibney reported 0 open-market buys worth $0 and 1 open-market sell worth $82k on SEC Form 4; the latest was sold $82k of AURA on Jun 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Anthony S Gibney's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony S Gibney has 0.
Where does Anthony S Gibney file Form 4?
Anthony S Gibney has filed Form 4 at AURA (Aura Biosciences, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.